ALNY241220P410000
- 0.00
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $296
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $296
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Announces Target Price $272
Scotiabank Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $384
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $275
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Alnylam Downgraded at Wolfe on Doubts Over Amvuttra Growth
Alnylam Pharmaceuticals Analyst Ratings
Wolfe Research Downgrades Alnylam Pharmaceuticals(ALNY.US) to Sell Rating, Announces Target Price $205
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Alnylam Pharma's Promising Pipeline and Strong Financials Justify Buy Rating and $400 Target